Beam Therapeutics Inc. — Q1 2020 Form 10-Q Summary
Business context and reporting period
Beam is a research-stage biotechnology company developing precision genetic medicines using proprietary base-editing technology. The filing covers the unaudited quarter ended March 31, 2020, compared with the quarter ended March 31, 2019. All programs remained in research or preclinical development, with no product candidates approved for sale and no product revenue.
Financial performance and position
| Metric | Q1 2020 | Q1 2019 | Change |
|---|---|---|---|
| License revenue | $6 thousand | $0 | +$6 thousand |
| Research and development expense | $21.5 million | $9.2 million | +$12.4 million |
| General and administrative expense | $6.8 million | $3.9 million | +$2.9 million |
| Loss from operations | $(28.4) million | $(13.1) million | $(15.2) million |
| Net loss | $(30.5) million | $(13.6) million | $(16.8) million |
| Net loss attributable to common stockholders | $(31.7) million | $(16.6) million | $(15.2) million |
| Basic and diluted loss per share | $(1.03) | $(2.86) | Improved primarily due to higher share count |
| Operating cash flow | $(27.4) million | $(25.9) million | $(1.5) million |
Revenue was immaterial, so revenue-based margins were not meaningful. The company expects continuing operating losses and negative operating cash flow for the foreseeable future.
- Cash and cash equivalents were $126.1 million at March 31, 2020, compared with $37.2 million at December 31, 2019.
- Marketable securities were $127.4 million, bringing cash, cash equivalents and marketable securities to $253.4 million.
- Total assets were $322.6 million; accumulated deficit was $233.5 million.
- Net cash provided by financing activities was $193.0 million, primarily from the IPO.
- Net cash used in investing activities was $76.8 million, primarily for net purchases of marketable securities of approximately $73.0 million and property and equipment of $3.0 million.
- Equipment financing liabilities totaled $7.0 million, and lease liabilities totaled $28.8 million. The company also disclosed a future MIT lease with anticipated undiscounted payments of $168.7 million that had not commenced and was not recorded on the balance sheet.
- Stock-based compensation expense was $2.8 million, compared with $0.9 million in the prior-year quarter.
Material changes versus the prior comparable period
- R&D expense increased 135%, driven by higher laboratory supplies and outsourced services, personnel costs, facilities costs, stock compensation and a Bio Palette patent milestone.
- R&D headcount increased from 56 to 110 employees, while general and administrative headcount increased from 9 to 24 employees.
- G&A expense increased 73%, reflecting organizational growth, public-company costs, personnel and stock compensation.
- The company completed its February 2020 IPO, issuing 12,176,471 shares at $17.00 per share for $207.0 million of gross proceeds and approximately $188.3 million of net proceeds.
- All outstanding preferred stock converted into 29,127,523 shares of common stock upon the IPO. A one-for-4.4843 reverse stock split became effective in January 2020.
- Success payment derivative liabilities related to Harvard and the Broad Institute increased from $7.8 million to $10.5 million, generating $2.7 million of additional expense.
- In March 2020, the company recognized $2.3 million of R&D expense and related accrued liability for a Bio Palette patent milestone that became probable.
Guidance, outlook, commentary and risks
- Management expected cash, cash equivalents and marketable securities at March 31, 2020 to fund operations for at least the next 12 months, but stated that additional financing will be required to support continuing operations and growth.
- Management expected R&D and G&A expenses to increase as preclinical programs advance, IND-enabling work begins, personnel are added and public-company infrastructure expands.
- The company expected to pursue additional preclinical milestones during 2020, begin IND-enabling studies in 2020 and submit an initial wave of IND filings beginning in 2021, subject to successful development and potential COVID-19-related delays.
- COVID-19 did not significantly affect first-quarter results, but office access was restricted and most employees worked remotely. Management warned that future disruptions could affect laboratories, suppliers, manufacturing, preclinical timelines, regulatory interactions and access to capital.
- Principal risks include the unproven nature of base editing, off-target or unintended edits, delivery and manufacturing challenges, regulatory uncertainty, dependence on third parties, competition, intellectual-property disputes and the need for substantial additional capital.
- License agreements contain potential development, regulatory and commercial milestones, royalties, maintenance obligations and success payments. No development or regulatory milestones or royalties were considered probable and recognized during the quarter under the Harvard, Broad, Editas, Prime Medicine or Verve arrangements.
- No material legal proceedings were reported. Management concluded disclosure controls and procedures were effective, with no material changes to internal control over financial reporting.
Important facts for investors to verify
- Whether the $253.4 million liquidity estimate remains sufficient as R&D spending and preclinical or clinical activities accelerate.
- Progress toward 2020 preclinical milestones, IND-enabling studies and planned initial IND filings beginning in 2021.
- The effect of COVID-19 on laboratory operations, suppliers, contract manufacturers, regulatory timelines and financing conditions.
- Changes in Harvard and Broad Institute success payment liabilities and any future milestone, royalty or licensing obligations.
- The status and strength of intellectual-property rights, including interference and opposition proceedings and licenses covering key technologies.
- Future share dilution from equity financing, stock options and restricted stock; 49.1 million common shares were outstanding at March 31, 2020 and 51.5 million at May 8, 2020.